Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PLEC | Q15149 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 10/20 | 0.46 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | GNG2 | P59768 | 1/20 | 0.44 |
| ▸ | GNB1 | P62873 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762533 | 0.86 | USP2 (0.52) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL23318855 | 0.82 | USP2 (0.66) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL20256560 | 0.81 | USP2 (0.59) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL13273546 | 0.81 | USP2 (0.67) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL12708320 | 0.78 | MEN1 (0.68) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL841016 | 0.77 | MEN1 (0.60) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL840985 | 0.77 | USP2 (0.59) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL107875 | 0.76 | USP2 (0.76) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL14433567 | 0.76 | MEN1 (0.68) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL29591827 | 0.76 | USP2 (0.76) | USP2MEN1POLBKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | OLIPASS CORPORATION (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319540-B2 | HIF 1-alpha antisense oligonucleotides | HIF1A, HIF1AN, UPF1 | USP2 2494/4885MEN1 1939/4885POLB 180/4885 |
| US-20210292767-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | HIF1A, HIF1AN, UPF1 | USP2 2494/4885MEN1 1939/4885POLB 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.